Fmr LLC Altimmune, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Fmr LLC holds 7,894 shares of ALT stock, worth $58,652. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,894

Previous 11,112 28.96%

Holding current value

$58,652

Previous $113,000 53.98%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$5.91 - $10.23 $19,018 - $32,920	-3,218 Reduced 28.96%	7,894 $52,000
Q1 2024 May 13, 2024	SELL	$8.22 - $13.81 $419,170 - $704,227	-50,994 Reduced 82.11%	11,112 $113,000
Q4 2023 Feb 13, 2024	SELL	$2.14 - $11.62 $10,573 - $57,414	-4,941 Reduced 7.37%	62,106 $698,000
Q3 2023 Nov 13, 2023	BUY	$2.4 - $3.45 $159,031 - $228,607	66,263 Added 8451.91%	67,047 $174,000
Q2 2023 Aug 11, 2023	SELL	$3.45 - $5.97 $4,067 - $7,038	-1,179 Reduced 60.06%	784 $2,000
Q1 2023 May 11, 2023	SELL	$4.19 - $16.83 $1,357 - $5,452	-324 Reduced 14.17%	1,963 $8,000
Q4 2022 Feb 13, 2023	SELL	$8.74 - $16.45 $335,843 - $632,107	-38,426 Reduced 94.38%	2,287 $37,000
Q3 2022 Nov 10, 2022	BUY	$10.67 - $22.41 $425,946 - $894,607	39,920 Added 5034.05%	40,713 $520,000
Q2 2022 Aug 12, 2022	BUY	$3.94 - $11.77 $1,122 - $3,354	285 Added 56.1%	793 $9,000
Q1 2022 May 13, 2022	BUY	$5.9 - $9.45 $2,997 - $4,800	508 New	508 $3,000
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $8 - $16	-1 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$9.85 - $16.46 $9 - $16	1 New	1 $0

Others Institutions Holding ALT

# of Institutions

191

Shares Held

42.4M

Call Options Held

1.05M

Put Options Held

582K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $364M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account